Clinical Effects Of Ticagrelor Versus Clopidogrel On Coronary Slow Flow In ST-elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention

Objective:To evaluate clinical effects of ticagrelor versus clopidogrel on coronary slow flow in ST-elevation myocardial infarction(STEMI) patients undergoing primary percutaneous coronary intervention(PCI). Methods:Consecutive 260 STEMI patients undergoing primary PCI from April 2014 to February 2015 were retrospectively enrolled. Based on the type of P2Y12 inhibitor taken before the procedure, patients were divided into two groups:ticagrelor group (n=84) and clopidogrel group (n=176). Coronary slow flow and perioperative bleeding events were the study endpoints. Results: Patients in ticagrelor group showed a decreased risk for slow flow after primary PCI procedure compared with clopidogrel group (OR:0.333,95%CI:0.118-0.941, p<0.05). No significant difference was found in either major (OR:1.076,95%CI:0.484-2.389, p=0.857) or minor (OR:1.218,95%CI:0.688-2.156, p=0.500) bleeding events between ticagrelor group and clopidogrel group. Conclusions:For STEMI patients undergoing primary PCI procedure, ticagrelor versus clopidogrel could reduce the risk of coronary slow flow, without increasing perioperative major or minor bleeding events.